NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,207.13 +444.10 (+2.50%) CRUDE OIL
79.06 +0.06 (+0.08%) GOLD FUTURES
2,313.40 +2.40 (+0.10%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,013.05 +1,066.55 (+2.32%)
Fate Therapeutics, Inc. (FATE)
After hours:
| Previous close | 4.0900 |
| Open | 4.1300 |
| Bid | 4.0500 x 300 |
| Ask | 4.1000 x 800 |
| Day's range | 3.9250 - 4.2200 |
| 52-week range | 1.6300 - 8.8300 |
| Volume | |
| Avg. volume | 2,638,286 |
| Market cap | 466.51M |
| Beta (5Y monthly) | 1.68 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
Key Therapeutic Mechanisms of Clinical Activity for Autoimmune Diseases, including B cell Depletion, Tissue Infiltration and Immune Reconstitution Data, from Phase 1 Study of FT819 in Relapsed / Refractory B-cell Malignancies to be Highlighted Patient Enrollment Initiated in Phase 1 Study of FT819 Off-the-shelf, CD19-targeted, iPSC-derived CAR T-cell Therapy for Systemic Lupus Erythematosus SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage bio
- GlobeNewswire
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will present at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024 at 2:15 PM ET. A live webcast
- GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that on April 1, 2024 the Company granted restricted stock units (RSUs) representing 6,400 shares of its common stock to one newly-hired non-executive employee. The grant was approved
